9 Honest Facts About Ashwagandha for Perimenopause Anxiety and Cortisol Before You Add It to Your Stack
The anxiety that arrives in perimenopause has a particular quality to it — it shows up at 3am, it feels disproportionate, and it makes you want to fix it with something you can control. That's exactly why ashwagandha is so appealing. Just make sure you're reaching for it with accurate information rather than wishful thinking.
Learn more about Rose →Ashwagandha is an adaptogen, not a hormone — the mechanism matters
Ashwagandha (Withania somnifera) works primarily by modulating the hypothalamic-pituitary-adrenal (HPA) axis, which governs the body's cortisol stress response — it does not directly raise or replace estrogen, progesterone, or any other reproductive hormone. This distinction is important because some perimenopause supplement marketing implies a hormonal effect that the evidence does not support. Women looking for relief from estrogen-driven symptoms like hot flashes or vaginal dryness should not expect ashwagandha to address those mechanisms.
There is a specific RCT in menopausal women — and it showed real results
A 2021 randomized, double-blind, placebo-controlled trial published in the journal Menopause looked at 91 perimenopausal and menopausal women who took 300mg of ashwagandha root extract twice daily for eight weeks. Participants showed statistically significant reductions in menopausal symptom scores, self-reported anxiety, and hot flash frequency compared to placebo. This is one of the few supplement trials that used an actual menopausal population rather than extrapolating from general-adult or male-dominant studies, which makes it more directly applicable.
Cortisol reduction is the most consistently replicated finding across trials
Multiple randomized controlled trials in stressed but otherwise healthy adults have found that ashwagandha supplementation (typically 240–600mg daily of root extract) produces measurable reductions in serum cortisol, with one 2019 meta-analysis in Medicine reporting reductions of roughly 15–30% over 8–12 weeks. For perimenopausal women, whose already-dysregulated HPA axis can amplify anxiety and disrupt sleep, this cortisol-lowering effect is the most evidence-backed reason to consider the herb. The effect appears dose-dependent and disappears when supplementation stops, so it is not a permanent reset.
The anxiety benefit is real but modest — it is not equivalent to pharmaceutical anxiolytics
Studies using validated anxiety scales (GAD-7, DASS-21, PSS) consistently show ashwagandha outperforms placebo for perceived stress and anxiety symptoms, but the effect sizes are moderate, typically in the range of 15–25% symptom reduction. For women whose perimenopause anxiety is severe, functionally impairing, or meets criteria for an anxiety disorder, this level of effect is unlikely to be sufficient as a standalone intervention. It is more accurately positioned as a useful adjunct or a lower-rung option for subclinical anxiety, not a replacement for evidence-based treatment.
It may improve sleep quality through a different pathway than most sleep supplements
Ashwagandha contains a compound called triethylene glycol, found predominantly in the leaf, which has shown sleep-inducing properties in animal models; the root extract also appears to improve sleep through HPA-axis calming rather than sedation. A 2019 RCT in PLOS ONE found that 300mg of root extract twice daily significantly improved sleep onset latency, total sleep time, and sleep quality scores in adults with insomnia. For perimenopausal women whose sleep disruption is partly cortisol-driven rather than purely hot-flash-driven, this mechanism is worth understanding.
Ashwagandha is contraindicated with thyroid medication — this is not a minor footnote
Ashwagandha has demonstrated thyroid-stimulating activity in clinical studies, raising T3 and T4 levels, which means it can potentiate the effect of levothyroxine and similar thyroid medications and potentially push a woman into hyperthyroid territory. Given that autoimmune thyroid conditions are common in perimenopausal women and often underdiagnosed, this interaction deserves more than a passing mention. Any woman on thyroid medication or with known thyroid dysfunction should discuss ashwagandha with her prescribing clinician before starting it.
Rare but documented cases of liver injury have been reported
The World Journal of Gastroenterology and several pharmacovigilance databases have documented cases of ashwagandha-associated hepatotoxicity (liver injury), most resolving after discontinuation but some requiring medical intervention. These cases are rare relative to the volume of people using the supplement, but they are not theoretical — and the mechanism is not yet fully understood, suggesting individual susceptibility may play a role. Women with pre-existing liver conditions, those on hepatotoxic medications, or those who drink alcohol regularly should factor this into their decision.
The dose and extract type in the studies matter more than the label claim
Most of the positive clinical trial data uses standardized root extract (not leaf, not whole-plant powder) at doses of 240–600mg per day, with some trials using a proprietary extract standardized to withanolide content — and supplement labels frequently obscure whether a product matches these specifications. A product listing '500mg ashwagandha' without specifying root vs. leaf, standardization percentage, or extraction method may bear little functional resemblance to what was studied. Reading past the front-of-label dose claim to the supplement facts panel is essential for any meaningful comparison to the trial evidence.
Ashwagandha does not address the hormonal root cause of perimenopause anxiety — it manages a downstream symptom
The anxiety, cortisol dysregulation, and sleep disruption of perimenopause are substantially driven by declining estrogen's effect on GABA receptors, serotonin pathways, and the HPA axis — and ashwagandha does not touch estrogen levels. For women whose anxiety is primarily hormonal in origin, managing cortisol without addressing the estrogen deficit is treating a symptom rather than the mechanism, which may be appropriate short-term but is worth naming honestly. Women who find ashwagandha helpful should be aware it is not a substitute for exploring whether hormone therapy or other evidence-based hormonal interventions are appropriate for their situation.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.